OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
REDWOOD CITY, Calif., Feb. 25, 2016 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will report fourth quarter and full year 2015 financial results after market close on Thursday, March 3, 2016. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial results and provide a company update.
| Live Call: | U.S. | 855 890 8665 |
| International | 720 634 2938 | |
| Passcode | 50851945 | |
| Live Webcast: | Codexis IR Website | |
| The webcast will be archived for 30 days. | ||
| Replay: | U.S. | 855 859 2056 |
| International | 404 537 3406 | |
| Passcode | 50851945 | |
| The replay will be available for 48 hours | ||
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
| CONTACT: | Investors |
| LHA | |
| Jody Cain, 310 691 7100 | |
| [email protected] | |
| Media | |
| That’s Nice | |
| Guy Tiene, 212 366 4455 | |
| [email protected] |
